Clinical Trial

FXS6837 for the Treatment of IgAN Patients

Name: FXS6837 for the Treatment of IgAN Patients — clinical trial record (NCT07502638)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of FXS6837 capsules in IgAN patients. About 60 patients dignosed with primary IgAN will be enrolled and randomized to three cohorts and take different dosage of FXS6837 or placebo capsules orally according to protocol.

Trial Details

NCT Number	NCT07502638
Lead Sponsor	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Conditions	IgAN
Enrollment	60 participants
Start Date	2026-03-31
Primary Completion	2027-09-12 (estimated)
Study Completion	2027-11-14 (estimated)
Updated on ClinicalTrials.gov	2026-03-31